Invea names Jason Fenton to its Board
Invea Therapeutics has appointed Jason Fenton to its Board of Directors. “We are honored to have a recognized advisor join our board of directors. Jason has...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Invea Therapeutics has appointed Jason Fenton to its Board of Directors. “We are honored to have a recognized advisor join our board of directors. Jason has...
Hartford HealthCare and Connecticut Innovations have announced a partnership they sayy will support 20 new startups in Hartford over the next two years. The partnership calls on Connecticut...
View this email in your browser Weekly Roundup – December 15, 2022 Congratulations to Dr. Ranjit Bindra on being recognized as the 2022 BioCT Entrepreneur of the Year! Dr. Bindra...
High-paying jobs in science, technology, engineering and math (STEM) are expected to be the fastest-growing occupations in Connecticut through 2030, according to a report by...
New Haven, Conn., December 13, 2022 — Dr. Ranjit Bindra of Yale University has been named the 2022 BioCT Entrepreneur of the Year. Dr. Bindra is an internationally...
Ivy Biomedical Systems, a privately-held Branford medical device manufacturer, has received approval to build a research and corporate headquarters building near the town’s border with...
View this email in your browser Weekly Roundup – December 8, 2022 This week BioCT Innovation Commons welcomed a group from Students United Way (United Way of Southeastern Connecticut)....
View this email in your browser We are excited to be back in person for the largest industry networking event in the state! Join the...
Researchers in the UConn Department of Biomedical Engineering —a shared department between the UConn Schools of Dental Medicine, Medicine, and Engineering—have unlocked a new strategy using sugar...
Rallybio has become the latest company to hitch its antibody drug development efforts to AbCellera. The partners will co-develop up to five rare disease therapeutic targets...